Effects of fenoterol/ipratropium bromide on FEV1 and hyperinflation in Thai COPD patients
Keywords:
COPD, fenoterol, ipratropium bromide, lung volume, FEV1, hyperinflationAbstract
Background: Patients with chronic obstructive pulmonary disease (COPD) usually suffer from breathlessness caused by chronic progressive worsening of airway obstruction and lung hyperinflation.
Objective: This study aimed to evaluate the effects of fenoterol hydrobromide and ipratropium bromide combination on lung function parameters in Thai COPD patients. We also compared the effects from two commercially available products; Aerobidol® metered-dose inhaler (MDI) and Berodual® inhaler.
Methods: A double-blind, randomized cross-over study was conducted in 31 COPD patients from outpatient service, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. To compare the responses of both inhalers on lung volume parameters, patients were randomized to be challenged by either Aerobidol® MDI or Berodual® inhaler. Spirometry and body plethysmography were performed before and after 60 min of each inhalation administration. All patients were switched to the other inhaler in the same manner after one-week washout period. A change of lung volume parameters including forced expiratory volume in the first second (FEV1), inspiratory capacity (IC), functional residual capacity (FRC), and residual volume (RV) were statistically compared by using analysis of covariance.
Results: Thirty-one COPD patients were recruited into the study. Their average of age was 66.6 years with a median value of smoking of 40 pack-years. Severity of COPD according to post bronchodilator FEV1 % predicted was mainly in GOLD stage 2 and 3. Both Aerobidol® MDI and Berodual® inhaler significantly increased FEV1 and decreased RV from baseline values. No statistical difference in changes of FEV1, IC, FRC, and RV between these two inhalers were observed.
Conclusion: Acute bronchodilating effects of Aerobidol® MDI is comparable to Berodual® inhaler in Thai COPD patients.
Downloads
References
Global initiative for chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013 [cited 2018 Jul 10]. Available from: URL: http://www.goldcopd.org/ guidelines- global- strategyfor-diagnisis-management.pdf.
Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995;50:62-6. https://doi.org/10.1136/thx.50.1.62
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Report 2019 [cited 2019 Jul 10]. Available from: https://goldcopd.org/wp-content/uploads/2018/11/ GOLD- 2019-v1.7-FINAL-14Nov2018-WMS.pdf.
Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504. https://doi.org/10.1124/pr.111.004580
Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2005;2:272-81. https://doi.org/10.1513/pats.200505-047SR
Rammeloo RH, Luursema PB, Sips AP, Beumer HM, Wald FD, Cornelissen PJ. Therapeutic equivalence of a fenoterol/ipratropium bromide combination (Berodual) inhaled as a dry powder and by metered dose inhaler in chronic obstructive airway disease. Respiration 1992;59:322-6.
https://doi.org/10.1159/000196081
Kässner F, Hodder R, Bateman ED. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease. Drugs 2004;64:1671-82. https://doi.org/10.2165/00003495-200464150-00005
Ruffin RE, McIntyre E, Crockett AJ, Zielonka K, Alpers JH. Combination bronchodilator therapy in asthma. J Allergy Clin Immunol 1982;69:60-5. https://doi.org/10.1016/0091-6749(82)90089-6
Levin DC, Little KS, Laughlin KR, Galbraith JM, Gustman PM, Murphy D, et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Am J Med 1996;100:40S-48S. https://doi.org/10.1016/S0002-9343(96)80073-8
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. https://doi.org/10.1183/09031936.05.00034805
Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511-22.
https://doi.org/10.1183/09031936.05.00035005
Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40. https://doi.org/10.1183/09041950.005s1693
Liu JP, Chow SC. Sample size determination for the two one sided tests procedure in bioequivalence. J Pharmacokinet Biopharm 1992;20:101-4. https://doi.org/10.1007/BF01143188
Saenghirunvattana S, Kongngeon V, Aeimrerksiri B, Jerathamopart P, Thamakumpee K, Reechaipichitkul W, et al. Chronic obstructive pulmonary diseases in Thailand: incidence, prevalence, present status and future trends. J Med Assoc Thai 2001;84:1407-11.
Cooper CB. Assessment of pulmonary function in COPD. Semin Respir Crit Care Med 2005 ;26:246-52.
https://doi.org/10.1055/s-2005-869543
O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1395-9.
https://doi.org/10.1164/ajrccm.163.4.2007026
Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General considerations for lung function testing. Eur Respir J 2005;26:153-61. https://doi.org/10.1183/09031936.05.00034505
O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001;18:914-20. https://doi.org/10.1183/09031936.01.00216501
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68. https://doi.org/10.1183/09031936.05.00035205
Hughes JA, Tobin MJ, Bellamy D, Hutchison DCS. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax 1982;37:667-70. https://doi.org/10.1136/thx.37.9.667
Teale C, Morrison JFJ, Jones PC, Muers MF. Reversibility tests in chronic obstructive airways disease: their predictive value with reference to benefit from domiciliary nebuliser therapy. Respir Med 1991;85:281-4. https://doi.org/10.1016/S0954-6111(06)80097-1
Kilfeathera SA, Ponitzb HH, Beckc E, Schmidtd P, Leee A, Bowenf I, Hesseg Ch. Improved delivery of ipratropium bromide/fenoterol from Respimats Soft MistTM Inhaler in patients with COPD. Respir Med 2004;98:387-97. https://doi.org/10.1016/j.rmed.2003.12.007
Hanania NA, Sharafkhaneh A, Celli B, Decramer M, Lystig T, Kesten S, Tashkin D. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res 2011,12:6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Chulalongkorn Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
